A drugs worth question keeps poping up like a bobber on a sunny warm lake. The problem with AVXL 2-73 is its probable wide application in the CNS world. The example is Merck's Keytruda which has the proven multiple applications alone and in combinations in the Oncology world. Here is that discussion again from last Feb.
----
Worth....as the science starts to prove it's self and topic of our discussion seems to gravitate towards what's all worth? .....to us - "worth the wait" - to those who suffer...."priceless". What will transpire will depend on a number of factors, how the science applies, how broad is the application (# of diseases), worldwide dist our drugs and competition. What is the assured will be benefit to "millions' and we will receive both the joy of helping others and monetary reward.
From a Jantuary post as to what Merck faces with "Keytruda".
"Steady.....the questions of what Anavex 2-73 might cost has been a constant topic on the board for some years. As discussed, it is very complicated due to the possibly large number of CNS diseases it might be effective in and the varying severity of those diseases. How would you differentiate price per dose between the sure death sentence of late Alzheimers and the dose for early Rett Syndrome. We've also dicussed the possible parallel between Merck's Keytruda and its many applications in oncology. Although, effective cancer treatments come at a premium, an effective drug for Alzheimers, Parkinson's, ALS and MS would push a drug's cost in that direction. Long term prophylactic use lies between critical disease use and an over the counter drug cost. But, then how do you justify the former with the latter?
From Keytuda's website:
"figuring out what you might pay out of pocket for a prescription medicine can be confusing. What you pay will depend on many factors, including your insurance situation and if there are financial support options available to you. At Merck, we believe that you should be better able to understand what you can expect to pay out of your own pocket for your prescription medicine.
The list price for each indicated dose of KEYTRUDA when given every 3 weeks is $9,869.94. The list price for each indicated dose of KEYTRUDA when given every 6 weeks is $19,739.88.* The total cost of KEYTRUDA over the course of treatment is the same, whether given every 3 weeks or every 6 weeks. Most people will not pay the list price, although it may have an impact on your out-of-pocket costs. The amount you pay will depend on many factors, including your insurance situation. The information below will help you better estimate what you may pay for your prescription medicine based on your insurance situation and also cover financial assistance that may be available to you.† For the actual out-of-pocket cost of your treatment, talk to your insurance provider, who knows the details of your plan if you have insurance, or contact your oncologist’s office for help."
Market Data 
Markets 
AI
